Skip to content
Fred Cohen
<< Back

Fred E. Cohen M.D., D.Phil.

Fred E. Cohen, M.D., D.Phil., F.A.C.P., has served as a director since January 2007.  Dr. Cohen is a TPG Partner and Managing Director, having joined TPG in 2001, and serves as co-head of TPG’s biotechnology group.  Dr. Cohen is also a former member of the faculty at the University of California, San Francisco, where he taught and conducted research from 1988 through 2014.  Dr. Cohen also serves as a director of the following public companies:  Genomic Health Inc., a company focused on providing actionable genomic health information; Five Prime Therapeutics, Inc., a clinic-stage biotechnology company focused on discovering and developing novel protein therapeutics; Tandem Diabetics Care, Inc., a medical device company that designs, develops and commercializes products for people with insulin-dependent diabetes;

BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development of novel, small-molecule drugs that block key enzymes involved in infectious and rare diseases; Roka BioScience, Inc., a food safety diagnostics business; and CareDx, Inc., a molecular diagnostics business focused on organ transplant recipients.  He is a member of the Institute of Medicine of the National Academy of Sciences and the American Academy of Arts and Sciences.  Dr. Cohen holds a Bachelor of Science degree in Molecular Biophysics and Biochemistry from Yale University, a D.Phil. in Molecular Biosphysics from Oxford University, where he was a Rhodes Scholar, and an M.D. from Stanford Univeristy.